Each film-coated tablet contains :
HBV is indicated for the treatment of chronic Hepatitis
B and evidence of hepatitis B virus (HBV) replication in
patients with decompensated liver disease or active
inflammation and/or fibrosis.
Lamivudine (ß-L-2',3'-dideoxy-3'-thiacytidine), one
of the dideoxycytidine (ddC) analogue NRTIs, is
the first nucleoside analogue approved to
treat chronic HBV infection and has been
shown to benefit various categories of patients.
These include HBe-positive and -negative patients,
non-responders to interferon-
therapy, and patients with decompensated
Lamivudine’s D-isomer is less active against HBV
replication and more cytotoxic than the L-isomer.
Both the D- and L-isomers of 2',3'-dideoxy-
3'-thiauridine were found to be inactive
against HBV replication, and the susceptibility
of the thiacytidine stereoisomers to cytidine
and/or deoxycytidine deaminase was suspected
to be the reason. In fact, the racemic
mixture and the D-isomer of
2',3'-dideoxy-3'-thiacytidine were deaminated
with partially purified human deaminase and were
found to be processed to the
D-isomer of the thiauridine, while lamivudine and
ddC were not. Despite the intracellular stability
of its cytosine base, ddC was less effective than
lamivudine in a cell culture system. Until
recently, it was thought that the potency of
lamivudine reflected the higher incorporation
efficiency into newly synthesized DNA by the viral DNA
polymerase. Lamivudine and ddC are
phosphorylated to their triphosphates and
then the triphosphates act as chain terminators during
viral and cellular DNA synthesis.
EPIVIR Tablets and Oral Solution are contraindicated in
patients with previously demonstrated clinically
significant hypersensitivity to any of the components of
Dosage: The recommended dosage of Lobivir HBV is 100 mg once daily
or as per the physician’s advice.